Can a new PET tracer light up Alzheimer's plaques in the living brain?

NCT ID NCT07764679

Recruiting now Diagnosis Sponsor: HTA Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This phase III trial is evaluating whether an experimental PET imaging agent, [18F]Fluorbetazine, can accurately detect amyloid-beta plaques in the brain—a hallmark of Alzheimer's disease. The study will include about 400 adults aged 40 and older with normal cognitive function, mild cognitive impairment (MCI), or Alzheimer's dementia. Participants receive a single injection of the tracer, and the PET images are compared against a true standard to measure the test's sensitivity and specificity. The goal is to see if this tracer can reliably help diagnose Alzheimer's-related cognitive decline.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental PET imaging tracer called [18F]Fluorbetazine injection
What this could lead to: If successful, this could provide a more accurate and accessible way to detect Alzheimer's-related brain plaques, aiding earlier diagnosis and better clinical trials.
What could go wrong: The trial is still in phase III, and the tracer's accuracy and safety need confirmation. It may not be widely available or may have false positives/negatives.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE (AD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER'S DISEASE (AD) MILD COGNITIVE IMPAIRMENT (MCI)

Contacts and locations

Locations

Peking Union Medical College Hospital
RECRUITING

Beijing, Beijing Municipality, 102413, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.